This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $20.91, moving +0.34% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Verona Pharma PLC American Depositary Share (VRNA) closed at $20.06, marking a -1.43% move from the previous day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $19.51, moving -0.46% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $18.85 in the latest trading session, marking a -0.05% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $21.78, moving +1.59% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $21.43 in the latest trading session, marking a +0.4% move from the prior day.
Verona (VRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.
Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.50, moving +0.72% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed the most recent trading day at $22.05, moving -1.21% from the previous trading session.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $20.50 in the latest trading session, marking a -1.44% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $22.53 in the latest trading session, marking a -0.75% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $23.69 in the latest trading session, marking a -0.96% move from the prior day.
Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) closed at $23.76 in the latest trading session, marking a -1% move from the prior day.
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences
by Zacks Equity Research
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.
4 Drug Stocks That More Than Doubled This Year
by Zacks Equity Research
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's What Could Help Verona Pharma PLC American Depositary Share (VRNA) Maintain Its Recent Price Strength
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 95% Upside in Verona Pharma PLC American Depositary Share (VRNA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 95.5% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110%
by Zacks Equity Research
The mean of analysts' price targets for Verona Pharma PLC American Depositary Share (VRNA) points to a 109.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
All You Need to Know About Verona Pharma PLC American Depositary Share (VRNA) Rating Upgrade to Strong Buy
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).